• Clinical Insights: July 7, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Endari™ (L-glutamine oral powder) – July 7, 2017 – The U.S. Food and Drug Administration approved Endari (L-glutamine oral powder) for patients age five years and older… Read more »

  • Clinical Insights — March 2016 Issue

    Welcome to the March edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Briviact® (brivaracetam)  February 19, 2016 – The U.S. Food and Drug Administration (FDA) approved Briviact® (brivaracetam) as an add-on treatment to other medications to treat partial onset… Read more »